Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lemzoparlimab + azacitidine
- Development stage
- Unknown
- Lead developer
- I-MAB
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Lemzoparlimab + azacitidine is an investigational combination therapy for hematologic malignancies, particularly higher-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Lemzoparlimab is a novel humanized monoclonal antibody targeting CD47, a cell surface protein that delivers a "don't eat me" signal to macrophages. By blocking CD47, lemzoparlimab enables macrophage-mediated phagocytosis of leukemic cells. Azacitidine is a well-established hypomethylating agent used in the treatment of MDS and AML. The combination has demonstrated strong anti-leukemic activity in preclinical studies and early-phase clinical trials, with encouraging response rates and manageable safety profiles. Lemzoparlimab’s design aims to minimize binding to normal red blood cells, potentially reducing the risk of severe anemia compared to other anti-CD47 antibodies[1][2][5].
- Brand names
- TJ011133TJ-011133TJ 011133
- Other names
- lemzoparlimab + azacitidine
02
Targets
CD47 (Cluster of Differentiation 47)DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on lemzoparlimab + azacitidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lemzoparlimab + azacitidine.